A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...
If you could inject yourself with a substance that purports to make you tanner, fitter, and healthier, would you? Many people ...
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...
Kardigan(TM), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced ...
Tonlamarsen “suppresses hepatic angiotensinogen production,” Laffin told the media ahead of the late-breaking session. “We know that AGT suppression reduces blood pressure among patients taking zero ...
Monthly injections of tonlamarsen lowered AGT but didn’t reduce BP in patients already on multiple antihypertensive drugs.
A new RNA-based therapy aims to address one of cardiology’s most persistent challenges: the heart’s inability to regenerate after injury.
The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused ...
Results presented here showed platelet-rich plasma injection within 6 months of total shoulder arthroplasty may lead to an ...
Hundreds of people who visited Club Chemistry in Canterbury on 5, 6 or 7 March were told to come forward for preventative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results